Evidence map›Paper›PMID 42543073›Full record

ArticleBiomedical chromatography : BMC2026

Assessing Dazhu Hongjingtian: Protection Against Acute Hypoxic Organ Damage and Analysis of Its Main Pharmaceutical Components.

Chunyan Ou, Xia Gao

Abstract read
In one paragraph

Article in Biomedical chromatography : BMC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Chunyan OuSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.ORCID https://orcid.org/0000-0001-7638-9946
Xia GaoJiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dazhu Hongjingtian (DZ), a traditional Tibetan medicine used for altitude sickness and blood stasis syndrome, currently lacks comprehensive pharmacological and quality control data. This study evaluated its antihypoxic effects in mice and established an HPLC-MS/MS method for quantifying 12 bioactive constituents. Acute hypoxic injury was induced by 12-h normobaric hypoxia (10% O

Indexed as

Drugs, Chinese HerbalHypoxiaAnimalsChromatography, High Pressure LiquidLinear ModelsMaleMiceOxidative StressReproducibility of ResultsTandem Mass SpectrometryDrugs, Chinese HerbalantihypoxicDazhu Hongjingtian water extract (DZE)HPLC‐MS/MSpharmaceutical components

Identifiers

PMID42543073
PMCPMC13429270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.